Back to People

Raj Basak, Ph.D.

Associate

About

Raj Basak is an Associate with F-Prime Capital and works across the healthcare sub-sectors including therapeutics, medical technology, and life-sciences tools. Prior to joining F-Prime, Raj was a member of the Healthcare Investment Banking team at Goldman Sachs in New York where he worked on over $15 billion in announced financing and M&A transactions across biopharma.

Raj received his Ph.D. in Molecular Biophysics & Biochemistry from Yale University and was a part of the Program in Physics, Engineering, and Biology (PEB). Raj’s doctoral research focused on studying the biophysical mechanisms underlying nociception in sensory neurons. While in graduate school, Raj was also a Canaan-Yale fellow with Canaan Partners and an analyst with Certara.

Prior to graduate school, Raj worked in laboratories at Columbia University Medical Center and Brown University. His research has been published in Biophysical Journal, Nature, Science Translational Medicine, among others. Raj also holds a B.S. in Physics with Research Honors from The Macaulay Honors College at The City College of New York, where he was awarded the Ward medal. His undergraduate thesis focused on interrogating field theory approaches to quantum tunnelling.

  • Amber Therapeutics is developing Amber-UI, a breakthrough adaptive neuromodulation therapy to treat women suffering with mixed urinary incontinence with the hope of transforming the clinical outcome and quality of life of a large untreated population. Amber-UI runs on the Company’s fully implantable Picostim system that targets the pudendal nerve to both stimulate and sense physiological responses. The therapy is configurable to the individual’s need and can respond dynamically to different events, adapting as needed between modes of operation. Amber’s technology platform is highly versatile and can be used to explore other novel therapy applications in both the pelvis and the broader nervous system, demonstrated by the work being carried out by the Company’s academic partnerships. Learn more at www.amber-tx.com.

  • Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing its proprietary RNA interference platform.  Learn more at www.atalantatx.com.

  • RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness. Founded on pioneering research from the Institute of Molecular and Clinical Ophthalmology Basel (IOB), RhyGaze aims to restore vision and transform the lives of patients worldwide. IOB scientists Drs. Botond Roska, Bence György and Charles Gubser are the scientific founders of RhyGaze. The name RhyGaze derives from the Basel-German word for the Rhein (Rhy), on the banks of which the IOB is located. Learn more at www.rhygaze.com.

  • Tenvie is a biotechnology company committed to engineering small molecules that transform the treatment of neurological diseases. The company’s foundation is purpose-built with a diverse portfolio of small molecules and a proven team of CNS drug developers to rapidly deliver multiple clinical assets. Tenvie is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function. The company’s most advanced programs target NLRP3 and SARM1, with additional programs in preclinical development. For more information, please visit www.tenvie.com and follow the company on LinkedIn.